BioCentury | Sep 9, 2013
Finance

E round in the hand vs. IPO in the bush

The stars have yet to align for Argos Therapeutics Inc. 's pursuit of a public listing. An IPO attempt last year fizzled in poor market conditions, and when the window opened several months ago, the...
BC Week In Review | Sep 2, 2013
Clinical News

SGI-110: Phase I/II data

Top-line data from 67 evaluable AML patients who had a minimum follow up of 3 months in the Phase II portion of the open-label, U.S. Phase I/II SGI-110-01 trial showed that subcutaneous SGI-110 led to...
BC Extra | Aug 29, 2013
Top Story

Astex up on data for second-generation Dacogen

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) added $1.34 (24%) to $6.82 on Wednesday after reporting that subcutaneous once-daily SGI-110 led to an overall remission rate of 25% in 67 evaluable acute myelogenous leukemia (AML) patients in the...
BC Week In Review | Jul 1, 2013
Clinical News

SGI-110: Interim Phase I/II data

Interim data from 15 evaluable intermediate- and high-risk MDS patients who received prior azacitidine or decitabine therapy in the dose-escalation Phase I portion of the open-label, U.S. Phase I/II SGI-110-01 trial showed that subcutaneous SGI-110...
BC Week In Review | Apr 15, 2013
Clinical News

Nipent pentostatin data

Researchers presented long-term survival data from a previously published Phase III trial in hairy cell leukemia. A total of 241 patients were treated with Nipent every two weeks for 6-12 months (154 were previously untreated...
BC Week In Review | Dec 3, 2012
Clinical News

PLX cells regulatory update

Pluristem said FDA requested additional information and data to determine if the company's allogeneic, placental-derived expanded (PLX) cells qualify for Orphan Drug designation to treat aplastic anemia. According to the company, the agency acknowledged that...
BC Week In Review | Apr 23, 2012
Clinical News

SGI-110: Interim Phase I/II data

Interim data from 66 patients with MDS or AML in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that subcutaneous SGI-110 led to 2 complete responses and 1 partial response...
BC Week In Review | Feb 13, 2012
Clinical News

Dacogen decitabine regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-3, with 1 abstention, that Dacogen decitabine did not demonstrate a favorable benefit-risk profile to treat newly diagnosed acute myelogenous leukemia (AML) in patients 65 years and older. The...
BC Week In Review | Jan 23, 2012
Company News

Astex Pharmaceuticals, GlaxoSmithKline deal

Astex said it is terminating a 2009 deal with GlaxoSmithKline to discover cancer therapeutics based on epigenetic targets. GSK originally entered the deal with SuperGen Inc. , which merged last year with Astex Therapeutics Ltd. to...
BioCentury | Jan 23, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allos Therapeutics Inc. (NASDAQ:ALTH) was off $0.15 to $1.51 on Friday after EMA's CHMP recommended against conditional approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma. The MAA was...
Items per page:
1 - 10 of 507
BioCentury | Sep 9, 2013
Finance

E round in the hand vs. IPO in the bush

The stars have yet to align for Argos Therapeutics Inc. 's pursuit of a public listing. An IPO attempt last year fizzled in poor market conditions, and when the window opened several months ago, the...
BC Week In Review | Sep 2, 2013
Clinical News

SGI-110: Phase I/II data

Top-line data from 67 evaluable AML patients who had a minimum follow up of 3 months in the Phase II portion of the open-label, U.S. Phase I/II SGI-110-01 trial showed that subcutaneous SGI-110 led to...
BC Extra | Aug 29, 2013
Top Story

Astex up on data for second-generation Dacogen

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) added $1.34 (24%) to $6.82 on Wednesday after reporting that subcutaneous once-daily SGI-110 led to an overall remission rate of 25% in 67 evaluable acute myelogenous leukemia (AML) patients in the...
BC Week In Review | Jul 1, 2013
Clinical News

SGI-110: Interim Phase I/II data

Interim data from 15 evaluable intermediate- and high-risk MDS patients who received prior azacitidine or decitabine therapy in the dose-escalation Phase I portion of the open-label, U.S. Phase I/II SGI-110-01 trial showed that subcutaneous SGI-110...
BC Week In Review | Apr 15, 2013
Clinical News

Nipent pentostatin data

Researchers presented long-term survival data from a previously published Phase III trial in hairy cell leukemia. A total of 241 patients were treated with Nipent every two weeks for 6-12 months (154 were previously untreated...
BC Week In Review | Dec 3, 2012
Clinical News

PLX cells regulatory update

Pluristem said FDA requested additional information and data to determine if the company's allogeneic, placental-derived expanded (PLX) cells qualify for Orphan Drug designation to treat aplastic anemia. According to the company, the agency acknowledged that...
BC Week In Review | Apr 23, 2012
Clinical News

SGI-110: Interim Phase I/II data

Interim data from 66 patients with MDS or AML in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that subcutaneous SGI-110 led to 2 complete responses and 1 partial response...
BC Week In Review | Feb 13, 2012
Clinical News

Dacogen decitabine regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-3, with 1 abstention, that Dacogen decitabine did not demonstrate a favorable benefit-risk profile to treat newly diagnosed acute myelogenous leukemia (AML) in patients 65 years and older. The...
BC Week In Review | Jan 23, 2012
Company News

Astex Pharmaceuticals, GlaxoSmithKline deal

Astex said it is terminating a 2009 deal with GlaxoSmithKline to discover cancer therapeutics based on epigenetic targets. GSK originally entered the deal with SuperGen Inc. , which merged last year with Astex Therapeutics Ltd. to...
BioCentury | Jan 23, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allos Therapeutics Inc. (NASDAQ:ALTH) was off $0.15 to $1.51 on Friday after EMA's CHMP recommended against conditional approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma. The MAA was...
Items per page:
1 - 10 of 507